Amgen Says Its Drug Surpasses Rival in Preventing Fractures


Much of Amgen's (AMGN) future rests on its experimental bone drug denosumab, to be sold commercially as Prolia. The drug has had its ups and downs, but Amgen, the largest global biotech company, said on Monday that a pivotal third Phase 3 clinical trial pitting denosumab against Novartis's (NVS) Zometa showed that denosumab worked better.